دورية أكاديمية
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
| العنوان: | Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer. |
|---|---|
| المؤلفون: | Leon-Ferre RA; Department of Oncology, Mayo Clinic, Rochester, MN, USA. leonferre.roberto@mayo.edu., Whitaker KR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Suman VJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Hoskin T; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Giridhar KV; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Moore RM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Al-Jarrad A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., McLaughlin SA; Department of Surgery, Mayo Clinic, Jacksonville, FL, USA., Northfelt DW; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA., Hunt KN; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Conners AL; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Moyer A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Carter JM; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada., Kalari K; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Weinshilboum R; Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA., Wang L; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Ingle JN; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Knutson KL; Department of Immunology, Mayo Clinic, Jacksonville, FL, USA., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Boughey JC; Department of Surgery, Mayo Clinic, Rochester, MN, USA., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Villasboas JC; Division of Hematology, Mayo Clinic, Rochester, MN, USA. |
| المصدر: | Breast cancer research : BCR [Breast Cancer Res] 2024 Jun 10; Vol. 26 (1), pp. 97. Date of Electronic Publication: 2024 Jun 10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London, UK : BioMed Central Ltd Original Publication: London, UK : Current Science, c1999- |
| مواضيع طبية MeSH: | Neoadjuvant Therapy*/methods , Immunophenotyping* , Breast Neoplasms*/drug therapy , Breast Neoplasms*/immunology , Breast Neoplasms*/blood , Breast Neoplasms*/pathology, Humans ; Female ; Middle Aged ; Adult ; Aged ; Receptor, ErbB-2/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Leukocytes, Mononuclear/metabolism ; Biomarkers, Tumor/blood ; Prognosis ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/blood ; Triple Negative Breast Neoplasms/pathology ; Prospective Studies ; Treatment Outcome ; Chemotherapy, Adjuvant/methods |
| مستخلص: | Background: Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy (NAC) remains understudied. Methods: Peripheral blood mononuclear cells from 126 breast cancer patients enrolled in a prospective clinical trial (NCT02022202) were analyzed using Cytometry by time-of-flight with a panel of 29 immune cell surface protein markers. Kruskal-Wallis tests or Wilcoxon rank-sum tests were used to evaluate differences in immune cell subpopulations according to breast cancer subtype and response to NAC. Results: There were 122 evaluable samples: 47 (38.5%) from patients with hormone receptor-positive, 39 (32%) triple-negative (TNBC), and 36 (29.5%) HER2-positive breast cancer. The relative abundances of pre-treatment peripheral blood T, B, myeloid, NK, and unclassified cells did not differ according to breast cancer subtype. In TNBC, higher pre-treatment myeloid cells were associated with lower pathologic complete response (pCR) rates. In hormone receptor-positive breast cancer, lower pre-treatment CD8 + naïve and CD4 + effector memory cells re-expressing CD45RA (T Conclusions: Pre-treatment peripheral blood immune cell populations (myeloid in TNBC; CD8 + naïve T cells and CD4 + T Trial Registration: NCT02022202 . Registered 20 December 2013. (© 2024. The Author(s).) |
| References: | Breast Cancer. 2021 Jul;28(4):904-914. (PMID: 33629216) J Clin Oncol. 2014 Sep 20;32(27):2959-66. (PMID: 25071121) Lancet Oncol. 2022 Jan;23(1):149-160. (PMID: 34902335) Nat Med. 2018 Feb;24(2):144-153. (PMID: 29309059) Blood. 2011 Jan 20;117(3):808-14. (PMID: 20971955) J Clin Oncol. 2019 Mar 1;37(7):559-569. (PMID: 30650045) Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8. (PMID: 34653365) Nat Med. 2018 Aug;24(8):1277-1289. (PMID: 29988129) J Clin Oncol. 2017 Apr 1;35(10):1049-1060. (PMID: 28135148) PLoS One. 2009 Jul 29;4(7):e6412. (PMID: 19641607) Mod Pathol. 2016 Apr;29(4):347-58. (PMID: 26867783) J Gastrointest Oncol. 2016 Dec;7(6):848-859. (PMID: 28078109) Cancer Res. 2016 Jul 1;76(13):3702-10. (PMID: 27197192) Nat Rev Cancer. 2016 Jul;16(7):447-62. (PMID: 27339708) Clin Cancer Res. 2007 Sep 1;13(17):5133-43. (PMID: 17785568) Cell. 2018 Nov 1;175(4):1014-1030.e19. (PMID: 30343900) Ann Oncol. 2014 Aug;25(8):1544-50. (PMID: 24608200) Cancer Sci. 2022 Jan;113(1):53-64. (PMID: 34751489) Clin Cancer Res. 2020 Nov 1;26(21):5668-5681. (PMID: 32826327) Cell. 2018 Aug 23;174(5):1293-1308.e36. (PMID: 29961579) J Clin Oncol. 2013 Mar 1;31(7):860-7. (PMID: 23341518) Oncoimmunology. 2015 Jun 3;5(2):e1054598. (PMID: 27057426) Cell. 2016 May 5;165(4):780-91. (PMID: 27153492) Nat Rev Immunol. 2009 Mar;9(3):162-74. (PMID: 19197294) Immunity. 2017 Aug 15;47(2):323-338.e6. (PMID: 28813661) J Immunol. 2017 Jan 15;198(2):927-936. (PMID: 27986910) Clin Cancer Res. 2021 Sep 15;27(18):5062-5071. (PMID: 34266889) Ann Oncol. 2011 Aug;22(8):1736-47. (PMID: 21709140) Breast Cancer. 2018 May;25(3):284-291. (PMID: 29204848) J Cancer. 2021 Mar 15;12(10):2886-2892. (PMID: 33854589) Cytometry A. 2020 Feb;97(2):184-198. (PMID: 31737997) J Natl Cancer Inst. 2017 Jul 1;109(7):. (PMID: 28376176) Clin Cancer Res. 2021 Oct 1;27(19):5365-5375. (PMID: 34253579) Front Physiol. 2023 Jun 01;14:1107070. (PMID: 37324393) Comput Struct Biotechnol J. 2021 May 21;19:3160-3175. (PMID: 34141137) Breast Cancer Res Treat. 2018 Jan;167(1):89-99. (PMID: 28913760) Cytometry A. 2013 May;83(5):483-94. (PMID: 23512433) Lancet Oncol. 2018 Jan;19(1):40-50. (PMID: 29233559) Int J Cancer. 2016 Sep 1;139(5):1129-39. (PMID: 27074317) Cytometry A. 2015 Jul;87(7):636-45. (PMID: 25573116) Future Oncol. 2022 Jan;18(1):55-65. (PMID: 34608815) J Pathol. 2023 Aug;260(4):376-389. (PMID: 37230111) J Immunol. 2001 Jan 1;166(1):678-89. (PMID: 11123353) JAMA Oncol. 2023 Apr 1;9(4):490-499. (PMID: 36602784) Cancer Lett. 2013 Jun 10;333(2):222-8. (PMID: 23370224) J Leukoc Biol. 2015 Dec;98(6):913-22. (PMID: 26337512) N Engl J Med. 2020 Feb 27;382(9):810-821. (PMID: 32101663) NPJ Breast Cancer. 2021 Jul 5;7(1):86. (PMID: 34226563) JAMA. 2024 Apr 2;331(13):1135-1144. (PMID: 38563834) |
| معلومات مُعتمدة: | U19 GM061388 United States GM NIGMS NIH HHS; KL2 TR002379 United States TR NCATS NIH HHS; P50 CA116201 United States CA NCI NIH HHS; P30 CA015083 United States CA NCI NIH HHS; CTSA Grant Number KL2 TR002379 United States TR NCATS NIH HHS; U19 GM61388 Pharmacogenomics Research Network; R01 CA196648 United States CA NCI NIH HHS; P50CA 116201 Mayo Clinic Breast Cancer Specialized Program of Research Excellence Grant; P30 CA15083-40A2 Mayo Clinic Cancer Center Support Grant |
| فهرسة مساهمة: | Keywords: Biomarkers; Breast cancer; Chemotherapy; Immunology; Single cell technologies; Translational research |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02022202 |
| المشرفين على المادة: | EC 2.7.10.1 (Receptor, ErbB-2) 0 (Biomarkers, Tumor) EC 2.7.10.1 (ERBB2 protein, human) |
| تواريخ الأحداث: | Date Created: 20240610 Date Completed: 20240611 Latest Revision: 20240613 |
| رمز التحديث: | 20240613 |
| مُعرف محوري في PubMed: | PMC11165781 |
| DOI: | 10.1186/s13058-024-01848-z |
| PMID: | 38858721 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1465-542X |
|---|---|
| DOI: | 10.1186/s13058-024-01848-z |